Education
About Us
Working with TipRanks
Follow Us
CellaVision AB (SE:CEVI)
:CEVI
Earnings Data
Report Date
Apr 29, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
1.46Last Year’s EPS
1.3Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 06, 2025
|% Change Since: -23.24%
|Next Earnings Date:Apr 29, 2025
Earnings Call Sentiment|Neutral
The call reflected a mix of strong growth in EMEA and positive strategic developments, offset by challenges in the Americas and APAC regions, and increased expenses. Despite some regional and financial fluctuations, the company's strategic initiatives and growth in core areas provide a balanced outlook.Company Guidance
During the Q3 2024 earnings call for CEVI.ST, the executives provided guidance highlighting an organic growth of 9%, achieving a revenue of SEK 179 million compared to SEK 168 million from the previous year. The EBITDA margin was reported at 27%, equivalent to SEK 49 million. The company experienced strong sales in the EMEA region with a 50% sequential growth in instrument sales, while sales declined by 20% in the Americas due to political uncertainties affecting hospital order placements. APAC showed fluctuations, with a notable absence of shipments to China this quarter. Gross margins improved from 66% to 68%, largely driven by the implementation of price increases. Additionally, the company is progressing on strategic partnerships and clinical validation, aiming to launch a bone marrow product with a CE Mark in Europe by 2025. R&D expenses constituted 22% of sales, reflecting investments in maturing development programs, including advancements in FPM technology. The cash flow for the quarter stood at SEK 16 million, with inventory levels gradually decreasing towards normal levels.Strong Sales in EMEA
EMEA experienced very strong growth across multiple markets and product groups, achieving an all-time high in sales even after accounting for early orders.
Organic Growth and Improved Gross Margin
The company reported an organic growth of 9% and an increase in gross margin from 66% to 68%.
Strategic Partnership with Sysmex
Continued development of strategic partnership with Sysmex, including joint training and marketing activities.
Progress in Clinical Validation
Progress according to plan on clinical validations for the bone marrow product, with a launch expected in 2025.
Reagent Growth
Reagents showed an 11% growth, with significant performance in EMEA.
---
SE:CEVI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SE:CEVI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 06, 2025 | kr222.50 | kr205.00 | -7.87% |
| Oct 24, 2024 | kr275.50 | kr279.50 | +1.45% |
| Jul 19, 2024 | kr279.00 | kr257.50 | -7.71% |
| Apr 25, 2024 | kr237.62 | kr227.22 | -4.37% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does CellaVision AB (SE:CEVI) report earnings?
CellaVision AB (SE:CEVI) is schdueled to report earning on Apr 29, 2025, TBA Not Confirmed.
What is CellaVision AB (SE:CEVI) earnings time?
CellaVision AB (SE:CEVI) earnings time is at Apr 29, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of CellaVision AB stock?
The P/E ratio of CellaVision AB is N/A.
What is SE:CEVI EPS forecast?
SE:CEVI EPS forecast for the fiscal quarter 2025 (Q1) is 1.46.
---